$0.82
+0.04 (+5.26%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where TCRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional · 6 observational
Held by 8 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, MARSHALL WACE, LLP, +3 more) · FINRA short interest 2.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Long Term Follow-up Study of TScan TCR-T ProductsNCT06976736observationalIncidence of Treatment-Emergent Adverse Events (Safety and Tolerability) | — | Recruiting | Other: Observational | AML, ALL, MDS | 1,000 | Sep 2040 | ≤ 5,156 d | 2025-09-10 |
| A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell TransplantationNCT07702578Relapse-free survival (RFS)Non-randomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: TSC-101 · Other: Control | AML, MDS | 310 | Jun 2029 | ≤ 1,046 d | 2026-07-22 |
| A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune DiseaseNCT06587828observationalIdentify peptide targets together with their associated TCRs in patients with autoimmune diseases under study. | — | Recruiting | Procedure: Companion blood samples with procedure | Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Crohn&Amp;#39;s Disease, Birdshot Chorioretinitis | 300 | Jan 2027 | ≤ 165 d | 2025-11-24 |
| A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid TumorsNCT05973487Evaluate the safety of monotherapy and T- Plex combination TCR-TsNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Biological: TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702, TSC-202-A0201, TSC-204-A0201 + TSC-202-A0201, TSC-204-C0702 + TSC-202-A0201, TSC-200-A0201 + TSC-202-A0201, TSC-203-A0201 + TSC-202-A0201, TSC-204-A0101 + TSC-202-A0201, TSC-201-B0702 + TSC-202-A0201 | Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma | 840 | 2026-12-30 | in 133 d | 2025-11-17 |
| A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell TransplantationNCT05473910Occurrence of dose limiting toxicitiesNon-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: SOC + TSC-101, SOC + TSC-100 · Other: Control | AML, MDS | 310 | 2026-06-01actual | — | 2026-07-21 |
| A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid TumorsNCT05812027observationalFrequency of subjects with TAA expression, HLA typing and HLA loss. | — | Active, not recruiting | Diagnostic test: Tumor and HLA Profiling | Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma | 1,150 | 2026-01-01 | — | 2025-11-17 |
| A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.NCT05230186observationalSingle Cell Sequencing | — | Unknown status | Procedure: Tumor Biopsy | Solid Tumor, Adult | 200 | 2024-12-23 | — | 2022-02-09 |
| Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to Immune Checkpoint InhibitorsNCT04680416observationalSingle Cell Sequencing | — | Withdrawnsponsor's stated reason: Lack of patient samples | — | Renal Clear Cell Carcinoma | 0 | 2021-08-04actual | — | 2021-08-25 |
| Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral EpitopesNCT04397900observationalIdentify the viral epitopes of memory CD8+ T cells from individuals that have recovered from SARS-CoV-2 infection. | — | Completed | — | Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection, Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types | 80 | 2021-04-12actual | — | 2021-04-14 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19